Amazon Launches Weight Loss Drug Program With Primary Care Integration
Finn's Take· TL;DR- Amazon launches GLP-1 weight loss program through One Medical, offering pills starting at $149/month and injections at $299/month with same-day delivery.
- Integrates obesity treatment into primary care relationships, allowing clinicians to monitor progress and manage related conditions like diabetes and cardiovascular disease.
- Competes with Walmart and telehealth providers by leveraging logistics network, transparent pricing, and existing healthcare infrastructure from $3.9B One Medical acquisition.
Amazon Enters the Weight Loss Drug Market
Amazon has officially entered the booming weight loss drug market, launching a comprehensive GLP-1 management program through its One Medical primary care network. The company unveiled Tuesday a new program that aims to simplify access to popular GLP-1 treatments, with its primary care arm, Amazon One Medical, launching a GLP-1 management program that integrates obesity treatment into routine care. Obesity affects more than 40% of U.S. adults and contributes to nearly $173 billion in annual medical costs.
The move comes as major retailers race to capture demand for weight-loss medications. Amazon's push comes days after Walmart unveiled its own GLP-1 platform, underscoring how major retailers are racing to capture demand for weight-loss drugs, including new pill versions. Around 1 in 8 adults are currently taking the drugs, which can also treat chronic conditions like diabetes and heart disease, according to a poll last year by health policy researcher KFF.
Transparent Pricing and Convenient Delivery
The pharmacy now offers the newly FDA-approved Wegovy and Foundayo oral GLP-1 pills for weight management—with insurance coverage starting as low as $25 per month or cash-pay options starting at $149 per month for both oral medications. Injectable treatments, including Wegovy shots and Eli Lilly's Zepbound, begin at $299 per month when paid for without insurance, Amazon said. These prices align with current market rates but Amazon's competitive edge lies elsewhere.
Amazon's edge is in same-day delivery and convenience as it looks to leverage its logistics network and consumer reach into another corner of the medical system. Amazon Pharmacy offers transparent GLP-1 pricing with Same-Day Delivery to nearly 3,000 cities today, expanding to 4,500 by year-end 2026. For existing patients needing prescription renewals, the company also said it will offer on-demand prescription renewals, starting at $29 for message consultation and $49 for video care.
Primary Care Integration Sets Amazon Apart
Unlike standalone telehealth providers, Amazon is positioning its approach as more comprehensive by embedding GLP-1 treatment within primary care relationships. The new program integrates GLP-1 management into patients' broader primary care relationship, proactively managing how weight loss intersects with cardiovascular health, metabolic conditions, and overall health. The integrated approach means clinicians can monitor progress, adjust treatments, and address related health conditions like cardiovascular disease and diabetes, all as part of a patient's primary care relationship.
One Medical executives told Axios some patients are arriving from other providers "malnourished" or on improper doses, highlighting risks when care isn't closely managed. Sustainable weight loss isn't just about medication—it's about treating obesity as a chronic condition that requires ongoing medical supervision. This integrated model addresses gaps in the fragmented GLP-1 care landscape that has emerged with the surge of telehealth providers.
Market Impact and Future Outlook
The announcement immediately affected competitors in the space. Shares of Hims & Hers Health, Viking Therapeutics and others fell on the news as investors weighed competition fears. Amazon's entry leverages its existing healthcare infrastructure, having acquired primary care chain One Medical for $3.9 billion in 2023, a few years after Amazon launched its online pharmacy.
The timing is strategic as the GLP-1 market continues evolving rapidly. The GLP-1 market is evolving quickly, with new drug formats, more approved uses and broader insurance coverage expected to expand access. Oral versions of the drugs could attract patients who are hesitant about injections, while policy changes — including expanded Medicare access — could further expand the market. Amazon's comprehensive approach, combining primary care oversight with pharmacy logistics and transparent pricing, positions the company to capture significant market share as demand for these medications continues to grow.